| Identification | Back Directory | [Name]
GSK3145095 | [CAS]
1622849-43-7 | [Synonyms]
GSK3145095
RIPK1 inhibitor GS3145095
1H-1,2,4-Triazole-5-carboxamide, N-[(3S)-7,9-difluoro-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-3-(phenylmethyl)- | [Molecular Formula]
C20H17F2N5O2 | [MDL Number]
MFCD32062741 | [MOL File]
1622849-43-7.mol | [Molecular Weight]
397.38 |
| Chemical Properties | Back Directory | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:164.5(Max Conc. mg/mL);413.96(Max Conc. mM)
Ethanol:6.0(Max Conc. mg/mL);15.1(Max Conc. mM) | [form ]
Solid | [pka]
8.82±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM [1]. | [storage]
Store at -20°C | [References]
[1] Harris PA, ET AL. Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862. DOI:10.1021/acsmedchemlett.9b00108 |
|
|